全文获取类型
收费全文 | 22977篇 |
免费 | 2099篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 219篇 |
儿科学 | 617篇 |
妇产科学 | 582篇 |
基础医学 | 2696篇 |
口腔科学 | 406篇 |
临床医学 | 2336篇 |
内科学 | 4754篇 |
皮肤病学 | 384篇 |
神经病学 | 2192篇 |
特种医学 | 782篇 |
外国民族医学 | 3篇 |
外科学 | 3420篇 |
综合类 | 510篇 |
一般理论 | 43篇 |
预防医学 | 2479篇 |
眼科学 | 310篇 |
药学 | 1553篇 |
中国医学 | 30篇 |
肿瘤学 | 1783篇 |
出版年
2021年 | 350篇 |
2020年 | 201篇 |
2019年 | 396篇 |
2018年 | 497篇 |
2017年 | 342篇 |
2016年 | 315篇 |
2015年 | 406篇 |
2014年 | 565篇 |
2013年 | 839篇 |
2012年 | 1160篇 |
2011年 | 1189篇 |
2010年 | 741篇 |
2009年 | 659篇 |
2008年 | 1115篇 |
2007年 | 1200篇 |
2006年 | 1196篇 |
2005年 | 1171篇 |
2004年 | 1073篇 |
2003年 | 1000篇 |
2002年 | 921篇 |
2001年 | 606篇 |
2000年 | 643篇 |
1999年 | 576篇 |
1998年 | 291篇 |
1997年 | 215篇 |
1996年 | 224篇 |
1995年 | 235篇 |
1994年 | 179篇 |
1993年 | 170篇 |
1992年 | 431篇 |
1991年 | 420篇 |
1990年 | 362篇 |
1989年 | 373篇 |
1988年 | 336篇 |
1987年 | 320篇 |
1986年 | 299篇 |
1985年 | 317篇 |
1984年 | 269篇 |
1983年 | 223篇 |
1982年 | 171篇 |
1981年 | 147篇 |
1979年 | 240篇 |
1978年 | 174篇 |
1977年 | 143篇 |
1974年 | 150篇 |
1973年 | 191篇 |
1972年 | 186篇 |
1971年 | 158篇 |
1969年 | 147篇 |
1968年 | 140篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
961.
Managing Osteoporosis in Patients on Long‐Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research 下载免费PDF全文
Robert A Adler Ghada El‐Hajj Fuleihan Douglas C Bauer Pauline M Camacho Bart L Clarke Gregory A Clines Juliet E Compston Matthew T Drake Beatrice J Edwards Murray J Favus Susan L Greenspan Ross McKinney Jr Robert J Pignolo Deborah E Sellmeyer 《Journal of bone and mineral research》2016,31(10):1910-1910
962.
Incidence and Impact of Documented Eradication of Breast Cancer Axillary Lymph Node Metastases Before Surgery in Patients Treated With Neoadjuvant Chemotherapy 总被引:11,自引:0,他引:11
Henry M. Kuerer Aysegul A. Sahin Kelly K. Hunt Lisa A. Newman Tara M. Breslin Fred C. Ames Merrick I. Ross Aman U. Buzdar Gabriel N. Hortobagyi S. Eva Singletary 《Annals of surgery》1999,230(1):72-78
OBJECTIVE: To determine the incidence and prognostic significance of documented eradication of breast cancer axillary lymph node (ALN) metastases after neoadjuvant chemotherapy. SUMMARY BACKGROUND DATA: Neoadjuvant chemotherapy is the standard of care for patients with locally advanced breast cancer and is being evaluated in patients with earlier-stage operable disease. METHODS: One hundred ninety-one patients with locally advanced breast cancer and cytologically documented ALN metastases were treated in two prospective trials of doxorubicin-based neoadjuvant chemotherapy. Patients had breast surgery with level I and II axillary dissection followed by additional chemotherapy and radiation treatment. Nodal sections from 43 patients who were originally identified as having negative ALNs at surgery were reevaluated and histologically confirmed to be without metastases. An additional 1112 sections from these lymph node blocks were obtained; half were stained with an anticytokeratin antibody cocktail and analyzed. Survival was calculated using the Kaplan-Meier method. RESULTS: Of 191 patients with positive ALNs at diagnosis, 23% (43 patients) were converted to a negative axillary nodal status on histologic examination (median number of nodes removed = 16). Of the 43 patients with complete axillary conversion, 26% (n = 11) had N1 disease and 74% (n = 32) had N2 disease. On univariate analysis, patients with complete versus incomplete histologic axillary conversion were more likely to have initial estrogen-receptor-negative tumors, smaller primary tumors, and a complete pathologic response in the primary tumor. The 5-year disease-free survival rates were 87% in patients with preoperative eradication of axillary metastases and 51% for patients with residual nodal disease after neoadjuvant chemotherapy. Of the 39 patients with complete histologic conversion for whom nodal blocks were available, occult nodal metastases were found in additional nodal sections in 4 patients (10%). At a median follow-up of 61 months, the 5-year disease-free survival rates were 87% in patients without occult nodal metastases and 75% in patients with occult nodal metastases. CONCLUSIONS: Neoadjuvant chemotherapy can completely clear the axilla of microscopic disease before surgery, and occult metastases are found in only 10% of patients with a histologically negative axilla. The results of this study have implications for the potential use of sentinel lymph node biopsy as an alternative to axillary dissection in patients treated with neoadjuvant chemotherapy. 相似文献
963.
964.
B. Lees S. W. Garland C. Walton D. Ross M. I. Whitehead J. C. Stevenson 《Osteoporosis international》1996,6(6):480-485
We have performed a 2-year prospective double-masked study to determine whether the bisphosphonate pamidronate can prevent bone loss in postmenopausal women and its optimal dosage regimen. One hundred and twenty-one such women (mean ± SD age 57.6±3.4 years; mean ± SD time since menopause 7.5±3.5 years) were randomized to receive either oral pamidronate (300 mg/day) for 4 weeks every 4 months (group A), oral pamidronate (150 mg/day) for 4 weeks every 2 months (group B) or identical placebo capsules (group C). Bone mineral density (BMD) measurements at the lumbar spine and proximal femur were performed at baseline and at 6-month intervals for 2 years using dual-energy X-ray absorptiometry. BMD at the lumbar spine (L2–4) increased significantly in groups A and B after 2 years of treatment (mean ± SD 2.8±2.1% and 3.0±2.9% respectively, bothp<0.001) but decreased in the placebo group (–1.6±3.1%,p<0.01). Identical results were seen for BMD at the femoral neck, which increased significantly in groups A and B after 2 years of treatment (1.2±2.3% and 1.3±2.9% respectively, bothp<0.05) but decreased in the placebo group (–1.9±3.9%,p<0.05). There were significant differences over 2 years between the groups at all anatomical sites (lumbar spine, femoral neck and trochanteric region, allp<0.001; Ward's triangle,p<0.01). However, there were no significant differences between groups A and B, suggesting that the two treatment regimens were equally effective in conserving BMD. There were, however, marked differences in tolerability between the two treatment regimens: 13 women (34%) in group A withdrew from the study because of side-effects, but only 5 women (12%) in group B, which was comparable with placebo. These data demonstrate that intermittent oral pamidronate will prevent bone loss from the lumbar spine and proximal femur of postmenopausal women, and that the more frequent but lower dose regimen is well tolerated. 相似文献
965.
Nigel Balfour Jamieson Alan K. Foulis Karin A. Oien Euan J. Dickson Clem W. Imrie Ross Carter Colin J. McKay 《Journal of gastrointestinal surgery》2011,15(3):512-524
Background
Following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma (PDAC), identification of peripancreatic fat tumor invasion promotes a tumor to stage T3. We sought to understand better the impact of histological peripancreatic fat invasion on prognosis and site of recurrence in a cohort of patients with PDAC. 相似文献966.
John T. Mullen M.D. Jeffrey H. Lee M.D. Henry F. Gomez M.D. William A. Ross M.D. Norio Fukami M.D. Robert A. Wolff M.D. Eddie K. Abdalla M.D. Jean-Nicolas Vauthey M.D. Jeffrey E. Lee M.D. Peter W. T. Pisters M.D. Douglas B. Evans M.D. 《Journal of gastrointestinal surgery》2005,9(8):1094-1105
Contemporary treatment programs for patients with potentially resectable pancreatic cancer often involve preoperative therapy.
When the duration of preoperative therapy exceeds 2 months, the risk of plastic endobiliary stent occlusion increases. Metal
stents have much better patency but may complicate subsequent pancreaticoduodenectomy (PD). We evaluated rates of perioperative
morbidity, mortality, and stent complications in 272 consecutive patients who underwent PD at our institution from May 2001
to November 2004. Of these 272 patients, 29 (11%) underwent PD after placement of a metal stent, 141 underwent PD after placement
of a plastic stent, 10 had PD after biliary bypass without stenting, and 92 had PD without any form of biliary decompression.
No differences were found between the Metal Stent group and all other patients in median operative time, intraoperative blood
loss, or length of hospital stay. No perioperative deaths occurred in the Metal Stent group versus 3 (1.2%) deaths in the
other 243 patients. The incidence of major perioperative complications was similar between the two groups, including the rates
of pancreatic fistula, intra-abdominal abscess, and wound infection. Furthermore, there were no differences in the perioperative
morbidity or mortality rates between patients who underwent preoperative biliary decompression with a stent of any kind (metal
or plastic) and those patients who underwent no biliary decompression at all. Metal stent-related complications occurred in
2 (7%) of 29 patients during a median preoperative interval of 4.1 months; in contrast, 75 (45%) of the 166 patients who had
had plastic stents experienced complications, including 98 stent occlusions, during a median preoperative interval of 3.9
months (P < 0.001). We conclude that the use of expandable metal stents does not increase PD-associated perioperative morbidity
or mortality, and as such an expandable metal stent is our preferred method of biliary decompression in patients with symptomatic
malignant distal bile duct obstruction in whom surgery is not anticipated, or in whom there is a significant delay in the
time to surgery.
Presented at the Forty-Sixth Annual Meeting of The Society for Surgery of the Alimentary Tract, Chicago, Illinois, May 14–18,
2005 (oral presentation).
Supported by the Lockton Fund for Pancreatic Cancer Research, The University of Texas M. D. Anderson Cancer Center, Houston,
Texas. 相似文献
967.
Autologous fascia lata transplantation for heart valve replacement: A two-year experience at the National Heart Hospital, London 下载免费PDF全文
Between April 1969 and December 1970, 201 patients underwent 262 valve replacements with frame-mounted autologous fascia lata valves in the aortic, mitral, and/or tricuspid positions at the National Heart Hospital. A single fascia lata valve was inserted in 146 patients and multi-valve replacement was performed in 55 instances. Hospital and late mortality are comparable with that following other procedures of heart valve replacement. One hundred and fifty-four patients with 193 fascia lata valves were available for follow-up. A retrospective analysis of this method of valve replacement has been undertaken to assess the suitability of fascia lata as a heart valve substitute as well as the clinical results achieved by this method of valve replacement. 相似文献
968.
Gennaro A. Carpinito Walter M. Stadler Joseph V. Briggman Gerald W. Chodak Paul A. Church Donald L. Lamm Paul H. Lange Edward M. Messing Robert M. Pasciak George B. Reservitz Robert N. Ross Daniel B. Rukstalis Michael F. Sarosdy Mark S. Soloway Robert P. Thiel Nicholas Vogelzang Cheryl L. Hayden 《The Journal of urology》1996,156(4):1280-1285
Purpose
The purpose of this trial was to evaluate an immunoassay for urinary nuclear matrix protein, NMP22,* as an indicator for transitional cell carcinoma of the urinary tract.Materials and Methods
Three groups of subjects participated in this trial of NMP22: 1--175 with transitional cell carcinoma, 2--117 with benign urinary tract conditions and 3--375 healthy volunteers. Each subject provided a single (3 voids) urine sample for analysis at the time of study entry. Each sample was assayed for the level of NMP22.Results
In normal healthy volunteers and in subjects with benign conditions median NMP22 levels were 2.9 and 3.3 units per ml., respectively. Median urinary NMP22 levels in patients with transitional cell carcinoma were significantly greater than in comparison subjects. Patients with active transitional cell carcinoma had significantly greater median urinary NMP22 levels than those with no evidence of disease (6.04 versus 4.11 units per ml., p = 0.027, 1-tailed Mann-Whitney U test). We noted no effect of tumor grade, extent of disease or exposure to intravesical therapy on urinary NMP22 levels.Conclusions
NMP22 is a promising urinary tumor marker for monitoring transitional cell carcinoma. Nuclear matrix proteins are a new class of tumor markers that represent the basis for the development of assays with increased efficacy for the detection and treatment of cancer. 相似文献969.